| |
|
INSHU: Reinfection following successful HCV DAA therapy among people with recent injecting drug use: the SIMPLIFY and D3FEAT studies
|
| |
| |
Reported by Jules Levin
7th International Symposium on Hepatitis Care in Substance Users
Cascais, Portugal
19 - 21 September 2018
Evan Cunningham, Grebely J, Dalgard O, Hajarizadeh B, Conway B, Powis J, Bruneau J, Feld JJ, Read P, Cooper C, Amin J, Bruggmann P, Lacombe K, Stedman C, Hellard ME, Marks P, Dunlop A, Quiene S, Moriggia A, Applegate TL, Litwin AH, Matthews GV, and Dore GJ on behalf of the SIMPLIFY and D3FEAT Study Groups
reinfections are simply an indicator that we are treating the right population. People who become reinfected are not only at risk of HCV infection but likely HCV transmission as well and so treatment among this population is crucial in order to reduce the incidence of new HCV cases. It is important reinfection cases are seen in this framework and patients are given access to timely retreatment without any stigma or discrimination.
| |
| |
| |
|
|
|
